INDEX TO VOLUME 45

SUBJECT INDEX

Adolescents
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22

Affective Disorders
Affective illness, dementia, and pseudodementia. Mar, 99-103
Arthur Watts: Research in clinical practice (editorial). Feb, 50
Bipolar illness preceded by anorexia nervosa in identical twins. June, 262-266
Depressive disorders in the community: The scene in Great Britain, 1965. Feb, 70-77
Funeral mania in recurrent bipolar affective disorders: Reports of three cases. July, 310-311
Predicting lithium requirements (letter with reply). Feb, 95-96
Predicting lithium dose (letter with reply). Feb, 95
Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms. Feb, 64-69
Protocol for the use of psychoactive drugs: Part III. Protocol for the treatment of bipolar affective disorder with lithium. May, 210-213

Age Regression
Spontaneous hypnotic age regression. Dec, 522-524

Agitation
Droperidol vs. haloperidol in the initial management of acutely agitated patients. July, 298-299

Agoraphobia
Secondary agoraphobia: Two case reports. Nov, 482-483

Alcohol and Alcoholism
Alcohol and marijuana: Comparison of use and abuse in regular marijuana users. Sept, 377-379
An evaluation of primary alcoholics with histories of violence. Jan, 3
Diagnostic validation of conjoint schizophrenia and alcoholism. July, 300-303
Disulfiram implantation: A dose response trial. June, 242-247
Disulfiram implantation (editorial). June, 241
Evaluation of lithium therapy for alcoholism. Dec, 494-499
Skid row alcoholism—An objective definition for use in detoxification and treatment planning. May, 214-216
Speculations on the cause(s) of alcoholism. Dec, 491-493
Studies of familial alcoholism: A review. Dec, Sec 2, 14-17

Alprazolam
Alprazolam and premenstrual syndrome (letter). Dec, 526
Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
Successful treatment of endogenous depression with alprazolam in a patient with recent cardiac disease: Case report. Nov, 480-481

Alzheimer's Disease
Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. Aug, 342-344
More on diagnosing Alzheimer's disease (letter). June, 280
Chemotherapy of cognitive disorders in geriatric subjects. May, 196-209

Amantidine
Amantidine in the neuroleptic malignant syndrome (letter). Dec, 526

Amitriptyline
Amitriptyline and contact lenses (letter). Apr, 188
Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293

Amoxapine
Amoxapine and extrapyramidal symptoms (letter). Sept, 407
Amoxapine-induced seizures: Case report. Aug, 358-359
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. Feb, 54-59

Analgesia
Alpha-2 agonists as analgesics (letter). Jan, 46

Animal Models
Pharmacology of nomifensine: A review of animal studies. Apr, Sec 2, 12-20
Physiologic and morphologic changes and incidence of neoplasms in mice and rats fed naltrexone HCl for 24 months. Sept, Sec 2, 11-14
Reproductive toxicity and teratology evaluations of naltrexone. Sept, Sec 2, 7-10

Animal Studies
ECT and tardive dyskinesia (letter). Apr, 188

Anorexia
Anorexia nervosa in a 45-year-old man. Sept, 405-406
Bipolar illness preceded by anorexia nervosa in identical twins. June, 262-266

Anticoagulants
Anticoagulant therapy in combined affective-organic disorders (letter). Oct, 444

Antidepressants; see also specific drugs
Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Antidepressant treatment of bulimia (letter). Oct, 443
Defining the boundaries of atypical depression. July, Sec 2, 19-21
Epilepsy, antidepressants, and the role of nomifensine. Apr, Sec 2, 39-42
Psychopharmacologic validation of atypical depression. July, Sec 2, 22-25
Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: The neurotransmitter receptor hypothesis of antidepressant action. Oct, Sec 2, 37-45
Relationship of desipramine plasma levels to therapeutic response: A critical reappraisal of the data. Oct, Sec 2, 46-49
Reply to Stewart JW: Antidepressant treatment of bulimia (letter). Oct, 443

Anxiety
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36
Panic anxiety: A new biological model. Aug, 323-330
Yohimbine and the model anxiety state. Dec, 512-515

Attention Deficit Disorder
Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. Nov, 473-476
Treatment of attention deficit and personality disorders with psychostimulants: Case report. Oct, 441-442

Biologic Markers; see also specific tests
A comparison of the cortisol suppression index and the dexamethasone suppression test. Oct, 431-432
Cortisol suppression index: A further evaluation. Oct, 437-438
Editorial. Oct, 430
Panic anxiety: A new biological model. Aug, 323-330

Biorhythms
Biorhythms revisited: Rhythm and blues? Oct, 426-429

Blood Dyscrasias
Thrombocytopenia associated with carbamazepine: Case report and review. July, 315-316

Borderline Personality Disorder
Dexamethasone suppression test and axis I diagnoses of inpatients with DSM-III borderline personality disorder. Apr, 150-153
DST and axis I diagnoses in borderline personality disorder (editorial). Apr, 149
Treatment of attention deficit and personality disorders with psychostimulants: Case report. Oct, 441-442

Bulimia
An open trial of MAO inhibitors in bulimia. May, 217-219
Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Antidepressant treatment of bulimia (letter with reply). Oct, 443
Bulimia in men: Report of three cases with neuroendocrine findings. Feb, 78-81
The dexamethasone suppression test in patients with bulimia. Dec, 508-511

Bupropion
Bupropion in the treatment of psychotic depression: Two case reports. May, 230-231

Carbamazepine
Carbamazepine and desipramine: A toxic reaction (letter). Aug, 360
Carbamazepine in chronic patients with EEG abnormalities (letter). Sept, 407
Carbamazepine-induced mania in two children: Case report. June, 272-274
Effects of carbamazepine on interictal psychopathology in TLE with ictal fear. Apr, 169-171
Lithium and carbamazepine (letter). Dec, 525
Thrombocytopenia associated with carbamazepine: Case report and review. July, 315-316

Cardiac Disease
The use of methylphenidate in depressed patients after cardiac surgery. Feb, 82-84
Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. Aug, 353-355
Successful treatment of endogenous depression with alprazolam in a patient with recent cardiac disease. Jan, 36-37

Cardiac Side Effects
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293
Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314

Catecholamines
Plasma catecholamine metabolites and early response to haloperidol. June, 248-251

Cephalothin
Neuropsychiatric sequelae and cephalothin (letter). Feb, 96

Cerebral Asymmetry
Cerebral asymmetry in subtypes of schizophrenia. Oct, 423-425

Character Disorders
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22

Children
Atypical somatoform disorder following infection in children—A depressive equivalent. Mar, 108-111
Carbamazepine-induced mania in two children: Case report. June, 272-274
Parental mental illness and psychiatric disorders in "at risk" children. Dec, 503-507
Slow-release methylphenidate: Problems when children chew tablets (letter). Dec, 525
Symptomatic thyroiditis and schizophrenia in a six-year-old girl. Jan, 36-37
The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report. May, 226-229

Chlorpromazine
Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study. Apr, 158-163

Cholecystolonin
Is cholecystokinin an antipsychotic agent? (letter). July, 317

Chronic Pain
Antidepressants in concomitant chronic back pain and de-

INDEX TO VOLUME 45

SUBJECT INDEX

Adolescents
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22

Affective Disorders
Affective illness, dementia, and pseudodementia. Mar, 99-103
Arthur Watts: Research in clinical practice (editorial). Feb, 50
Bipolar illness preceded by anorexia nervosa in identical twins. June, 262-266
Depressive disorders in the community: The scene in Great Britain, 1965. Feb, 70-77
Funeral mania in recurrent bipolar affective disorders: Reports of three cases. July, 310-311
Predicting lithium requirements (letter with reply). Feb, 95-96
Predicting lithium dose (letter with reply). Feb, 95
Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms. Feb, 64-69
Protocol for the use of psychoactive drugs: Part III. Protocol for the treatment of bipolar affective disorder with lithium. May, 210-213

Age Regression
Spontaneous hypnotic age regression. Dec, 522-524

Agitation
Droperidol vs. haloperidol in the initial management of acutely agitated patients. July, 298-299

Agoraphobia
Secondary agoraphobia: Two case reports. Nov, 482-483

Alcohol and Alcoholism
Alcohol and marijuana: Comparison of use and abuse in regular marijuana users. Sept, 377-379
An evaluation of primary alcoholics with histories of violence. Jan, 3
Diagnostic validation of conjoint schizophrenia and alcoholism. July, 300-303
Disulfiram implantation: A dose response trial. June, 242-247
Disulfiram implantation (editorial). June, 241
Evaluation of lithium therapy for alcoholism. Dec, 494-499
Skid row alcoholism—An objective definition for use in detoxification and treatment planning. May, 214-216
Speculations on the cause(s) of alcoholism. Dec, 491-493
Studies of familial alcoholism: A review. Dec, Sec 2, 14-17

Alprazolam
Alprazolam and premenstrual syndrome (letter). Dec, 526
Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
Successful treatment of endogenous depression with alprazolam in a patient with recent cardiac disease: Case report. Nov, 480-481

Alzheimer's Disease
Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. Aug, 342-344
More on diagnosing Alzheimer's disease (letter). June, 280
Chemotherapy of cognitive disorders in geriatric subjects. May, 196-209

Amantidine
Amantidine in the neuroleptic malignant syndrome (letter). Dec, 526

Amitriptyline
Amitriptyline and contact lenses (letter). Apr, 188
Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293

Amoxapine
Amoxapine and extrapyramidal symptoms (letter). Sept, 407
Amoxapine-induced seizures: Case report. Aug, 358-359
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. Feb, 54-59

Analgesia
Alpha-2 agonists as analgesics (letter). Jan, 46

Animal Models
Pharmacology of nomifensine: A review of animal studies. Apr, Sec 2, 12-20
Physiologic and morphologic changes and incidence of neoplasms in mice and rats fed naltrexone HCl for 24 months. Sept, Sec 2, 11-14
Reproductive toxicity and teratology evaluations of naltrexone. Sept, Sec 2, 7-10

Animal Studies
ECT and tardive dyskinesia (letter). Apr, 188

Anorexia
Anorexia nervosa in a 45-year-old man. Sept, 405-406
Bipolar illness preceded by anorexia nervosa in identical twins. June, 262-266

Anticoagulants
Anticoagulant therapy in combined affective-organic disorders (letter). Oct, 444

Antidepressants; see also specific drugs
Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Antidepressant treatment of bulimia (letter). Oct, 443
Defining the boundaries of atypical depression. July, Sec 2, 19-21
Epilepsy, antidepressants, and the role of nomifensine. Apr, Sec 2, 39-42
Psychopharmacologic validation of atypical depression. July, Sec 2, 22-25
Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: The neurotransmitter receptor hypothesis of antidepressant action. Oct, Sec 2, 37-45
Relationship of desipramine plasma levels to therapeutic response: A critical reappraisal of the data. Oct, Sec 2, 46-49
Reply to Stewart JW: Antidepressant treatment of bulimia (letter). Oct, 443

Anxiety
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36
Panic anxiety: A new biological model. Aug, 323-330
Yohimbine and the model anxiety state. Dec, 512-515

Attention Deficit Disorder
Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. Nov, 473-476
Treatment of attention deficit and personality disorders with psychostimulants: Case report. Oct, 441-442

Biologic Markers; see also specific tests
A comparison of the cortisol suppression index and the dexamethasone suppression test. Oct, 431-432
Cortisol suppression index: A further evaluation. Oct, 437-438
Editorial. Oct, 430
Panic anxiety: A new biological model. Aug, 323-330

Biorhythms
Biorhythms revisited: Rhythm and blues? Oct, 426-429

Blood Dyscrasias
Thrombocytopenia associated with carbamazepine: Case report and review. July, 315-316

Borderline Personality Disorder
Dexamethasone suppression test and axis I diagnoses of inpatients with DSM-III borderline personality disorder. Apr, 150-153
DST and axis I diagnoses in borderline personality disorder (editorial). Apr, 149
Treatment of attention deficit and personality disorders with psychostimulants: Case report. Oct, 441-442

Bulimia
An open trial of MAO inhibitors in bulimia. May, 217-219
Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Antidepressant treatment of bulimia (letter with reply). Oct, 443
Bulimia in men: Report of three cases with neuroendocrine findings. Feb, 78-81
The dexamethasone suppression test in patients with bulimia. Dec, 508-511

Bupropion
Bupropion in the treatment of psychotic depression: Two case reports. May, 230-231

Carbamazepine
Carbamazepine and desipramine: A toxic reaction (letter). Aug, 360
Carbamazepine in chronic patients with EEG abnormalities (letter). Sept, 407
Carbamazepine-induced mania in two children: Case report. June, 272-274
Effects of carbamazepine on interictal psychopathology in TLE with ictal fear. Apr, 169-171
Lithium and carbamazepine (letter). Dec, 525
Thrombocytopenia associated with carbamazepine: Case report and review. July, 315-316

Cardiac Disease
The use of methylphenidate in depressed patients after cardiac surgery. Feb, 82-84
Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. Aug, 353-355
Successful treatment of endogenous depression with alprazolam in a patient with recent cardiac disease. Jan, 36-37

Cardiac Side Effects
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293
Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314

Catecholamines
Plasma catecholamine metabolites and early response to haloperidol. June, 248-251

Cephalothin
Neuropsychiatric sequelae and cephalothin (letter). Feb, 96

Cerebral Asymmetry
Cerebral asymmetry in subtypes of schizophrenia. Oct, 423-425

Character Disorders
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22

Children
Atypical somatoform disorder following infection in children—A depressive equivalent. Mar, 108-111
Carbamazepine-induced mania in two children: Case report. June, 272-274
Parental mental illness and psychiatric disorders in "at risk" children. Dec, 503-507
Slow-release methylphenidate: Problems when children chew tablets (letter). Dec, 525
Symptomatic thyroiditis and schizophrenia in a six-year-old girl. Jan, 36-37
The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report. May, 226-229

Chlorpromazine
Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study. Apr, 158-163

Cholecystolonin
Is cholecystokinin an antipsychotic agent? (letter). July, 317

Chronic Pain
Antidepressants in concomitant chronic back pain and de-

pression: Doxepin and desipramine compared. Mar, Sec 2, 54-59
Depression caused by chronic pain. Mar, Sec 2, 30-38
Doxepin's effects on chronic pain and depression. Mar, Sec 2, 47-53
Cigarette Smoking
Pharmacologic basis and treatment of cigarette smoking. Dec, Sec 2, 24-34
Smoking and hyponatremia in psychiatric patients (letter). Aug, 360-361
Clomipramine
A comparison of clomipramine and doxepin in neurotic depression. Aug, 337-341
Clomipramine treatment for panic attacks in patients with mitral valve prolapse. Jan, 25-27
Clorazepate
Differential amnestic properties of short- and long-acting benzodiazepines. Feb, 51-53
Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. Oct, 411-413
CME Tests
CME tests. May, Sec 2, 60-64
Cocaine
The spectrum of cocaine abuse and its treatment. Dec, Sec 2, 18-23
Combination Therapy
Combined use of trazodone and phenelzine in depression: Case report. Apr, 182-183
The combined use of MAOIs and tricyclics. July, Sec 2, 67-69
Cognitive Dysfunction
Chemotherapy of cognitive disorders in geriatric subjects. May, 196-209
Community Mental Health
Neurosyphilis in community mental health clinics: A case series. Mar, 127-129
Compliance
Patient compliance with MAO inhibitor therapy. July, Sec 2, 78-80
The use of depot neuroleptics: Clinical experience in the United States. May, Sec 2, 5-12
Conversion Disorder
The validity of broadly defined hysteria and DSM-III conversion disorder: Outcome, family history, and mortality. June, 252-256
Cortisol Suppression Index
A comparison of the cortisol suppression index and the dexamethasone suppression test. Oct, 431-432
Cortisol suppression index: A further evaluation. Oct, 437-438
Dynamics of the cortisol suppression index in depression. Oct, 433-436
Editorial. Oct, 430
Cranial Electrotherapy Stimulation
Cranial electrotherapy stimulation treatment of cognitive brain dysfunction and chemical dependence. Feb, 60-63
Delirium
Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
Delusional Depression
Late-onset delusional depression: A distinct clinical entity? Aug, 347-349
Dementia
Affective illness, dementia, and pseudodementia. Mar, 99-103
A simple, reliable clinical behavioral scale for assessing demented patients. Jan, 23-24
Depression
A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder. Nov, 466-469
A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 73-77
Antidepressants in concomitant chronic back pain and depression: Doxepin and desipramine compared. Mar, Sec 2, 54-58
An overview of side effects and long-term experience with nomifensine from United States clinical trials. Apr, Sec 2, 96-99
A review of the clinical safety and tolerability of nomifensine. Apr, Sec 2, 89-95
Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. July, Sec 2, 44-48
A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 68-72
Bupropion in the treatment of psychotic depression: Two case reports. May, 230-231
Chronic disease and depression in the geriatric population. Mar, Sec 2, 18-24
Classification of depressive disorders: A multiaxial approach. July, Sec 2, 5-13
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Correlation of the Hamilton and Carroll depression rating scales: A replication study among psychiatric outpatients. Apr, 167-168
Depressed women with panic attacks. Sept, 367-369
Depression caused by chronic pain. Mar, Sec 2, 30-37
Depression: Relationship to somatization and chronic medical illness. Mar, Sec 2, 4-12
Diagnosing depression in the hospitalized patient with chronic medical illness. Mar, Sec 2, 13-17
Diagnosis and treatment of depression in the cancer patient. Mar, Sec 2, 25-29
Double-blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients. Apr, Sec 2, 43-46
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. Feb, 54-59
Double-blind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients. Apr, Sec 2, 52-55
Doxepin's effects on chronic pain and depression. Mar, Sec 2, 47-53
DSM-III, RDC, and ECT: Depressive subtypes and immediate response. Jan, 14-18
Dynamics of the cortisol suppression index in depression. Oct, 433-436
Effects of endogenicity and severity on consistency of standard depression rating scales. June, 260-261
Efficacy of nomifensine in different depressive syndromes. Apr, Sec 2, 85-88
Fluoxetine in depressed patients: A comparison with imipramine. Oct, 414-419
Hypothalamic-pituitary-adrenal axis activity and age in major depression. Mar, 120-121
Hysteroid dysphoria in depressed inpatients. Apr, 164-166
Long-term treatment of chronic depression: 15-year experience with doxepin HCl. Mar, Sec 2, 39-46
MAO inhibitor therapy in trichotillomania associated with depression: Case report. June, 267-268
Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. Apr, Sec 2, 56-59
Multicenter placebo-controlled evaluation of nomifensine treatment in depressed outpatients. Apr, Sec 2, 47-51
Nomifensine in the depressed elderly patient: Discussion. Apr, Sec 2, 102-103
Nomifensine in geriatric inpatients: A placebo-controlled study. Apr, Sec 2, 63-67
Nomifensine vs. imipramine in depressed inpatients. Apr, Sec 2, 60-62
Pharmacotherapy of geriatric depression. Oct, Sec 2, 30-36
Pooling 12 nomifensine studies for efficacy generalizability. Apr, Sec 2, 78-84
Possible clinical applications of laboratory tests in depression. Apr, Sec 2, 6-11
Problems with diagnostic criteria for depression. July, Sec 2, 14-18
Sex differences in inpatients with major depression. June, 257-259
Thyroid hormone and the TRH stimulation test in refractory depression. Aug, 345-346
Treatment of outpatients with desipramine. Oct, Sec 2, 17-22
Treatment-resistant depression in an elderly patient with pancreatic carcinoma: Case report. Oct, 439-440
Depression, Atypical
Defining the boundaries of atypical depression. July, Sec 2, 19-21
Psychopharmacologic validation of atypical depression. July, Sec 2, 22-25
Depressive Symptoms
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22
Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Atypical somatoform disorder following infection in children—A depressive equivalent. Mar, 108-111
Depressive psychopathology in male sleep apneics. July, 287-290
Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms. Feb, 64-69
Shy-Drager syndrome presenting as depression: Case report. Mar, 137-139
Symptom perception by nonpsychiatric physicians in evaluating for depression. July, Sec 2, 26-28
The use of methylphenidate in depressed patients after cardiac surgery. Feb, 82-84
Desipramine
Antidepressants in concomitant chronic back pain and depression: Doxepin and desipramine compared. Mar, Sec 2, 54-58
Carbamazepine and desipramine: A toxic reaction (letter). Aug, 360
Desipramine: An overview. Oct, Sec 2, 3-9
Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: The neurotransmitter receptor hypothesis of antidepressant action. Oct, Sec 2, 37-45
Treatment of outpatients with desipramine. Oct, Sec 2, 17-22
Use of desipramine in the medically ill. Oct, Sec 2, 23-29
Dexamethasone Suppression Test
A comparison of the cortisol suppression index and the dexamethasone suppression test. Oct, 431-432
Clinical utilization of the dexamethasone suppression test. Sept, 382-384
Clinical utilization of the dexamethasone suppression test in an inpatient setting. Sept, 393-396
Dexamethasone suppression test and treatment response. Sept, 387-389
Dexamethasone suppression test: Use of two different dexamethasone doses. Sept, 390-392
Editorial. Sept, 380
Dexamethasone suppression in depressed elderly outpatients. Sept, 397-398
False-positive dexamethasone suppression test results related to antipsychotic drug withdrawal: Case report. June, 275-276
Hypothalamic-pituitary-adrenal axis activity and age in major depression. Mar, 120-121
Neuroendocrine dysfunction and response to tricyclic antidepressants. Sept, 385-386
The dexamethasone suppression test in schizophrenia. Sept, 399-402
The dexamethasone suppression test in patients with bulimia. Dec, 508-511
Diagnosis/Classification
Classification of depressive disorders: A multiaxial approach. July, Sec 2, 5-13
DSM-III, RDC, and ECT: Depressive subtypes and immediate response. Jan, 14-18
DST and axis I diagnoses in borderline personality disorder (editorial). Apr, 149
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36
Dexamethasone suppression test and axis I diagnoses of inpatients with DSM-III borderline personality disorder. Apr, 150-153
Diagnostic validation of conjoint schizophrenia and alcoholism. July, 300-303
Hysteroid dysphoria in depressed inpatients. Apr, 164-166
Problems with diagnostic criteria for depression. July, Sec 2, 14-18
Schizo-affective disorder: Diagnostic criteria (letter with reply). Mar, 144-145
Suicidal behavior: A neglected issue in DSM-III (letter). June, 280
The validity of broadly defined hysteria and DSM-III conversion disorder: Outcome, family history, and mortality. June, 252-256

Diagnostic Studies
Depressed women with panic attacks. Sept, 367-369
Diazepam
Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. Oct, 411-413
Differential Diagnosis
Affective illness, dementia, and pseudodementia. Mar, 99-103
Chronic disease and depression in the geriatric population. Mar, Sec 2, 18-24
Diagnosing depression in the hospitalized patient with chronic medical illness. Mar, Sec 2, 13-17
Late-onset delusional depression: A distinct clinical entity? Aug, 347-349
More on diagnosing Alzheimer's disease (letter). June, 280
Multiple personality disorder in a hospital setting. Apr, 172-175
Shy-Drager syndrome presenting as depression: Case report. Mar, 137-139
Symptom perception by nonpsychiatric physicians in evaluating for depression. July, Sec 2, 26-28
Disulfiram
Disulfiram implantation: A dose response trial. June, 242-247
Disulfiram implantation (editorial). June, 241
Dothiepin
A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder. Nov, 466-469
Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293
Doxepin
A comparison of clomipramine and doxepin in neurotic depression. Aug, 337-341
Antidepressants in concomitant chronic back pain and depression: Doxepin and desipramine compared. Mar, Sec 2, 54-58
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Doxepin's effects on chronic pain and depression. Mar, Sec 2, 47-53
Long-term treatment of chronic depression: 15-year experience with doxepin HCl. Mar, Sec 2, 39-46
Dreams
Dream disturbances and flashbacks (letter). Jan, 46
Droperidol
Droperidol vs. haloperidol in the initial management of acutely agitated patients. July, 298-299
Drug Abuse and Addiction
Alcohol and marijuana: Comparison of use and abuse in regular marijuana users. Sept, 377-379
Clinical experience with naltrexone in suburban opioid addicts. Sept, Sec 2, 42-45
Drugs in the workplace. Dec, Sec 2, 4-8
Naltrexone: A clinical perspective. Sept, Sec 2, 25-28
Naltrexone induction: Psychologic and pharmacologic strategies. Sept, Sec 2, 29-38
Naltrexone in addicted business executives and physicians. Sept, Sec 2, 39-41
Naltrexone treatment in a jail work-release program. Sept, Sec 2, 49-52
Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. Sept, Sec 2, 46-48
The role of the National Institute on Drug Abuse in the development of naltrexone. Sept, Sec 2, 4-6
Use of naltrexone to extinguish opioid-conditioned responses. Sept, Sec 2, 53-56
Drug Dependence/Withdrawal
Cranial electrotherapy stimulation treatment of cognitive brain dysfunction and chemical dependence. Feb, 60-63
Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
False-positive dexamethasone suppression test results related to antipsychotic drug withdrawal: Case report. June, 275-276
Psychiatric disorders in opioid-dependent patients. Dec, Sec 2, 9-13
The spectrum of cocaine abuse and its treatment. Dec, Sec 2, 18-23
Withdrawal symptoms after long-term treatment with low-potency neuroleptics. Dec, 500-502
Dystonia
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Aug, 356-357
"Trick" movements in facial dystonia. Dec, 519-521
Electroconvulsive Therapy
ECT and tardive dyskinesia (letter). Apr, 188
Status epilepticus with unilateral ECT: Case report. Sept, 403-404
The efficacy of ECT in phencyclidine-induced psychosis. May, 220-222
Electroencephalography
Carbamazepine in chronic patients with EEG abnormalities (letter). Sept, 407
The EEG in obsessive-compulsive disorder. Mar, 122-124
Epidemiology
A controlled study of suicide pacts. Apr, 154-157
Arthur Watts: Research in clinical practice (editorial). Feb, 50
Depressive disorders in the community: The scene in Great Britain, 1965. Feb, 70-77
Psychiatric disorders among relatives of surgical controls. Oct, 420-422
The epidemiology of obsessive compulsive disorder. Nov, 450-457
Epilepsy
Effects of carbamazepine on interictal psychopathology in TLE with ictal fear. Apr, 169-171
Epilepsy, antidepressants, and the role of nomifensine. Apr, Sec 2, 39-42
Epileptic Kluver-Bucy syndrome: Case report. Feb, 87-88
Psychiatric aspects of complex partial seizures: Case report. June, 269-271
Status epilepticus with unilateral ECT: Case report. Sept, 403-404
Estrogen
A case of rapid mood cycling with estrogen: Implications for therapy. Jan, 34-35
Extrapyramidal Symptoms
Amoxapine and extrapyramidal symptoms (letter). Sept, 407
EPS associated with pipothiazines (letter with reply). Mar, 145
Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. Aug, 342-344
Family Studies
Differences in plasma cortisol after ingestion of ethanol in relatives of alcoholics and controls: Preliminary results. Sept, 374-376
Parental mental illness and psychiatric disorders in "at risk" children. Dec, 503-507
Studies of familial alcoholism: A review. Dec, Sec 2, 14-17
Fluphenazine
Fluoxetine in depressed patients: A comparison with imipramine. Oct, 414-419
Fluphenazine plasma levels and clinical response. Sept, 370-373
Flurazepam
Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. May, 192-195
Gambling
Profile of the pathological gambler. Dec, Sec 2, 35-38
Geriatric Patients
A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 68-72
A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 73-77
Chemotherapy of cognitive disorders in geriatric subjects. May, 196-209
Chronic disease and depression in the geriatric population. Mar, Sec 2, 18-24
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Dexamethasone suppression in depressed elderly outpatients. Sept, 397-398
Hypothermic coma associated with thioridazine in a myxedematous patient (letter). Apr, 188-189
Neurosyphilis and late onset mental changes in the elderly (letter). Nov, 484
Nomifensine in geriatric inpatients: A placebo-controlled study. Apr, Sec 2, 63-67
Nomifensine in the depressed elderly patient: Discussion. Apr, Sec 2, 102-103
Pharmacotherapy of geriatric depression. Oct, Sec 2, 30-36
Problems in the use of long-acting hypnotics in older patients. Apr, 176-177
The value of laboratory investigations in elderly psychiatric patients. Mar, 112-116
Treatment-resistant depression in an elderly patient with pancreatic carcinoma: Case report. Oct, 439-440
Haloperidol
Droperidol vs. haloperidol in the initial management of acutely agitated patients. July, 298-299
Plasma catecholamine metabolites and early response to haloperidol. June, 248-251
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Jan, 10-13
Hemodialysis
Lithium in a patient with renal failure on hemodialysis (letter). Oct, 444
Trazodone and hemodialysis (letter). Aug, 361
Homicide
Homicide in psychotics in France: A five-year study. Feb, 85-86
Hyponatremia
Smoking and hyponatremia in psychiatric patients (letter). Aug, 360-361
Hypotension
The treatment of phenelzine-induced hypotension with salt tablets: Case report. Feb, 89-90
Hypothalamic-Pituitary-Adrenal Axis
Differences in plasma cortisol after ingestion of ethanol in relatives of alcoholics and controls: Preliminary results. Sept, 374-376
Hypothalamic-pituitary-adrenal axis activity and age in major depression. Mar, 120-121
Hysteroid Dysphoria
Hysteroid dysphoria in depressed inpatients. Apr, 164-166
Hypnosis
Spontaneous hypnotic age regression. Dec, 522-524
Hysteria
The validity of broadly defined hysteria and DSM-III conversion disorder: Outcome, family history, and mortality. June, 252-256
Imipramine
A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric patients. Apr, Sec 2, 73-77
A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 68-72
Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. Feb, 54-59
Fluoxetine in depressed patients: A comparison with imipramine. Oct, 414-419
Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. Apr, Sec 2, 56-59
Nomifensine vs. imipramine in depressed inpatients. Apr, Sec 2, 60-62
Serum imipramine concentrations lower than plasma levels. Dec, 516-518
Isocarboxazid
Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. July, Sec 2, 44-48
Side effects of isocarboxazid. July, Sec 2, 53-58
The importance of dose in isocarboxazid therapy. July, Sec 2, 49-52
Kluver-Bucy Syndrome
Epileptic Kluver-Bucy syndrome: Case report. Feb, 87-88
Laboratory Analyses
Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. May, Sec 2, 50-59
Possible clinical applications of laboratory tests in depression. Apr, Sec 2, 6-11

Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Mar, 117-119
State dependence of noradrenergic activity in a rapidly cycling bipolar patient. July, 306-309
Tear lithium concentration: A measurement of dubious clinical value. July, 304-305
The value of laboratory investigations in elderly psychiatric patients. Mar, 112-116
Tyramine studies and the safety of MAOI drugs. July, Sec 2, 59-61

Lithium
Arthritis associated with lithium toxicity: Case report. Mar, 135-136
Evaluation of lithium therapy for alcoholism. Dec, 494-499
Lithium and carbamazepine (letter). Dec, 525
Lithium in a patient with renal failure on hemodialysis (letter). Oct, 444
Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. Aug, 342-344
Predicting lithium dose (letter with reply). Feb, 95
Predicting lithium requirements (letter). Feb, 95-96
Protocols for the use of psychoactive drugs: Part III. Protocol for the treatment of bipolar affective disorders with lithium. May, 210-213
Tear lithium concentration: A measurement of dubious clinical value. July, 304-305

Lorazepam
Differential amnestic properties of short- and long-acting benzodiazepines. Feb, 51-53
Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. Mar, 104-107

Loxapine
Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study. Apr, 158-163

Maintenance Treatment
Depot neuroleptics: The relevance of psychosocial factors—A United States perspective. May, Sec 2, 36-42
Long-term treatment of chronic depression: 15-year experience with doxepin HCl. Mar, Sec 2, 39-46
Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. May, Sec 2, 13-21
Psychosocial relevance and benefit of neuroleptic maintenance: Experience in the United Kingdom. May, Sec 2, 43-49

MAO Inhibitors
An open trial of MAO inhibitors in bulimia. May, 217-219
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36
Diethylpropion-induced psychosis reprecipitated by an MAO inhibitor: Case report. Mar, 130-131
Differential response patterns to MAO inhibitors and tricyclics. July, Sec 2, 70-77
MAO inhibitor therapy in trichotillomania associated with depression: Case report. June, 267-268
New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. July, Sec 2, 37-43
Patient compliance with MAO inhibitor therapy. July, Sec 2, 78-80
Practical aspects of MAO inhibitor therapy. July, Sec 2, 81-84
Reversibility of MAO inhibition (letter with reply). May, 234
Studies of selective and reversible monoamine oxidase inhibitors. July, Sec 2, 62-66
The combined use of MAOIs and tricyclics. July, Sec 2, 67-69
Tyramine studies and the safety of MAOI drugs. July, Sec 2, 59-61

Mania
Carbamazepine-induced mania in two children: Case report. June, 272-274
Funeral mania in recurrent bipolar affective disorders: Reports of three cases. July, 310-311
Mania induced by metoclopramide: Case report. Apr, 180-181
Manic pseudodementia: Case report. Mar, 132-134

Maprotiline
Atrial flutter and maprotiline: Case report. Jan, 31-33
Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Hepatotoxicity associated with maprotiline therapy: Case report. Apr, 178-179
Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314

Marijuana; see also Drug Abuse/Addiction
Alcohol and marijuana: Comparison of use and abuse in regular marijuana users. Sept, 377-379

Medical Illness
Atypical somatoform disorder following infection in children—A depressive equivalent? Mar, 108-111
Chronic disease and depression in the geriatric population. Mar, Sec 2, 18-24
Depression: Relationship to somatization and chronic medical illness. Mar, Sec 2, 4-12
Diagnosing depression in the hospitalized patient with chronic medical illness. Mar, Sec 2, 13-17
Diagnosis and treatment of depression in the cancer patient. Mar, Sec 2, 25-29
Hypothermic coma associated with thioridazine in a myxedematous patient (letter). Apr, 188-189
Lithium in a patient with renal failure on hemodialysis (letter). Oct, 444
Psychiatric aspects of complex partial seizures: Case report. June 269-271
Symptomatic thyroiditis and schizophrenia in a six-year-old girl. Jan, 36-37
The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report. May, 226-229
Trazodone and hemodialysis (letter). Aug, 361
Treatment-resistant depression in an elderly patient with pancreatic carcinoma: Case report. Oct, 439-440
Use of desipramine in the medically ill. Oct, Sec 2, 23-29

Memory
Differential amnestic properties of short- and long-acting benzodiazepines. Feb, 51-53

Methylphenidate
Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. Nov, 473-476
Slow-release methylphenidate: Problems when children chew tablets (letter). Dec, 525
The use of methylphenidate in depressed patients after cardiac surgery. Feb, 82-84

Metoclopramide
Mania induced by metoclopramide: Case report. Apr, 180-181

MHPG
State dependence of noradrenergic activity in a rapidly cycling bipolar patient. July, 306-309

Mitral Valve Prolapse
Clomipramine treatment for panic attacks in patients with mitral valve prolapse. Jan, 25-27

Multiple Personality Disorder
Multiple personality disorder in a hospital setting. Apr, 172-175

Naloxone
Endocrine and metabolic effects of opiate antagonists. Sept, Sec 2, 20-24

Naltrexone
Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. Sept, Sec 2, 15-19
Clinical experience with naltrexone in suburban opioid addicts. Sept, Sec 2, 42-45
Endocrine and metabolic effects of opiate antagonists. Sept, Sec 2, 20-24
Naltrexone: A clinical perspective. Sept, Sec 2, 25-28
Naltrexone in addicted business executives and physicians. Sept, Sec 2, 39-41
Naltrexone induction: Psychologic and pharmacologic strategies. Sept, Sec 2, 29-38
Naltrexone treatment in a jail work-release program. Sept, Sec 2, 49-52
Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. Sept, Sec 2, 46-48
Physiologic and morphologic changes and incidence of neoplasms in mice and rats fed naltrexone HCl for 24 months. Sept, Sec 2, 11-14
Reproductive toxicity and teratology evaluations of naltrexone. Sept, Sec 2, 7-10
The role of the National Institute on Drug Abuse in the development of naltrexone. Sept, Sec 2, 4-6
Use of naltrexone to extinguish opioid-conditioned responses. Sept, Sec 2, 53-56

National Institute on Drug Abuse
The role of the National Institute on Drug Abuse in the development of naltrexone. Sept, Sec 2, 4-6

Neuroleptic Malignant Syndrome
Amantadine in the neuroleptic malignant syndrome (letter). Dec, 526
Treatments for neuroleptic malignant syndrome (letter with reply). Mar, 144

Neuroleptics
A brief history of depot neuroleptics. May, Sec 2, 3-4
Beyond the therapeutic window: A case presentation. May, 223-225
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Jan, 28-30
Depot fluphenazine: Risk/benefit ratio. May, Sec 2, 28-35
Depot neuroleptics: The relevance of psychosocial factors—A United States perspective. May, Sec 2, 36-42
Drug-induced hyponatremia? (letter). July, 317
EPS associated with pipothiazines (letter with reply). Mar, 145
False-positive dexamethasone suppression test results related to antipsychotic drug withdrawal: Case report. June, 275-276
Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. May, Sec 2, 50-59
Hypokalemia-induced psychosis in a chronic schizophrenic patient. June, 277-279
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Aug, 331-336
Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. May, Sec 2, 13-21
Psychosocial relevance and benefit of neuroleptic maintenance: Experience in the United Kingdom. May, Sec 2, 43-49
Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Mar, 117-119
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Aug, 356-357
Seborrheic dermatitis: A newly reported side effect of neuroleptics. Mar, 125-126
The risk/benefit ratio of depot neuroleptics: A Scandinavian perspective. May, Sec 2, 22-27
Treatments for neuroleptic malignant syndrome (letter with reply). Mar, 144
The use of depot neuroleptics: Clinical experience in the United States. May, Sec 2, 5-12
Withdrawal symptoms after long-term treatment with low-potency neuroleptics. Dec, 500-502

Neurosyphilis
Neurosyphilis and late onset mental changes in the elderly (letter). Nov, 484
Neurosyphilis in community mental health clinics: A case series. Mar, 127-129

Neurotic Depression
A comparison of clomipramine and doxepin in neurotic depression. Aug, 337-341

Neurotransmitters
Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: The neurotransmitter receptor hypothesis of antidepressant action. Oct, Sec 2, 37-45

Nifedipine
Nifedipine treatment of Tourette's syndrome (letter). Aug, 360

Nomifensine
A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 73-77
An overview of side effects and long-term experience with nomifensine from United States clinical trials. Apr, Sec 2, 96-99
A review of the clinical safety and toierability of nomifensine. Apr, Sec 2, 89-95
A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 68-72

Double-blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients. Apr, Sec 2, 43-46
Double-blind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients. Apr, Sec 2, 52-55
Efficacy of nomifensine in different depressive syndromes. Apr, Sec 2, 85-88
Epilepsy, antidepressants, and the role of nomifensine. Apr, Sec 2, 39-42
Kinetics and metabolism of nomifensine. Apr, Sec 2, 21-25
Multicenter placebo-controlled evaluation of nomifensine treatment in depressed outpatients. Apr, Sec 2, 47-51
Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. Apr, Sec 2, 56-59
Nomifensine in geriatric inpatients: A placebo-controlled study. Apr, Sec 2, 63-67
Nomifensine in the depressed elderly patient: Discussion. Apr, Sec 2, 102-103
Nomifensine vs. imipramine in depressed inpatients. Apr, Sec 2, 60-62
Pharmacodynamics of nomifensine: A review of studies in healthy subjects. Apr, Sec 2, 33-38
Pharmacology of nomifensine: A review of animal studies. Apr, Sec 2, 12-20
Pooling 12 nomifensine studies for efficacy generalizability. Apr, Sec 2, 78-84
The pharmacokinetics and bioavailability of nomifensine maleate in healthy men. Apr, Sec 2, 26-32

Obsessive-Compulsive Disorder
The EEG in obsessive-compulsive disorder. Mar, 122-124
The epidemiology of obsessive compulsive disorder. Nov, 450-457

Occupational Health
Drugs in the workplace. Dec, Sec 2, 4-8

Oral Contraceptives
Possible antidepressant effect of oral contraceptives: Case report. Aug, 350-352

Organic Brain Disorders
Anticoagulant therapy in combined affective-organic disorders (letter). Oct, 444

Parkinsonism
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Jan, 28-30

Panic Attacks; see also Anxiety
Clomipramine treatment for panic attacks in patients with mitral valve prolapse. Jan, 25-27
Depressed women with panic attacks. Sept, 367-369

Panic Disorder
Propranolol therapy in a patient with panic disorder, tardive dyskinesia, and essential tremor (letter). Nov, 484-485

Patient Education
Practical aspects of MAO inhibitor therapy. July, Sec 2, 81-84

Pharmacokinetics
Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. Sept, Sec 2, 15-19
Kinetics and metabolism of nomifensine. Apr, Sec 2, 21-25
Pharmacodynamics of nomifensine: A review of studies in healthy subjects. Apr, Sec 2, 33-38
The pharmacokinetics and bioavailability of nomifensine maleate in healthy men. Apr, Sec 2, 26-32

Pharmacology
Pharmacology of nomifensine: A review of animal studies. Apr, Sec 2, 12-20

Pharmacotherapy
The pharmacotherapy-psychotherapy triangle: Psychiatrist, nonmedical psychotherapist, and patient. Nov, 458-459

Phencyclidine
The efficacy of ECT in phencyclidine-induced psychosis. May, 220-222

Phenelzine
Combined use of trazodone and phenelzine in depression: Case report. Apr, 182-183
The treatment of phenelzine-induced hypotension with salt tablets: Case report. Feb, 89-90

Phobias
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36

Physicians
Naltrexone in addicted business executives and physicians. Sept, Sec 2, 39-41
Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. Sept, Sec 2, 46-48
Symptom perception by nonpsychiatric physicians in evaluating for depression. July, Sec 2, 26-28

Plasma Levels
Beyond the therapeutic window: A case presentation. May, 223-225
Fluphenazine plasma levels and clinical response. Sept, 370-373
Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. May, Sec 2, 50-59
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Jan, 10-13
Predicting lithium dose (letter with reply). Feb, 95
Predicting lithium requirements (letter with reply). Feb, 95-96
Relationship of desipramine plasma levels to therapeutic response: A critical reappraisal of the data. Oct, Sec 2, 46-49
Serum imipramine concentrations lower than plasma levels. Dec, 516-518

Posttraumatic Stress Syndrome
Dream disturbances and flashbacks (letter). Jan, 46

Praxepam
Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. Oct, 411-413

Premenstrual Syndrome
Alprazolam and premenstrual syndrome (letter). Dec, 526

Priapism
Priapism associated with trazodone therapy: Case report. May, 232-233

Prison
Naltrexone treatment in a jail work-release program. Sept, Sec 2, 49-52

Propranolol
Propranolol therapy in a patient with panic disorder, tardive dyskinesia, and essential tremor (letter). Nov, 484-485

Pseudodementia
Affective illness, dementia, and pseudodementia. Mar, 99-103
Diethylpropion-induced psychosis reprecipitated by an MAO inhibitor: Case report. Mar, 130-131
Manic pseudodementia: Case report. Mar, 132-134

Psychosocial Therapy
Depot neuroleptics: The relevance of psychosocial factors—A United States perspective. May, Sec 2, 36-42
Psychosocial relevance and benefit of neuroleptic maintenance: Experience in the United Kingdom. May, Sec 2, 43-49

Psychosis
Assessment of SIADH in psychosis with a water-loading test: Case report. Jan, 40-41
Diethylpropion-induced psychosis reprecipitated by an MAO inhibitor: Case report. Mar, 130-131
Homicide in psychotics in France: A five-year study. Feb, 85-86
Hypokalemia-induced psychosis in a chronic schizophrenic patient. June, 277-279
Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Jan, 10-13
The efficacy of ECT in phencyclidine-induced psychosis. May, 220-222

Psychotherapy
The pharmacotherapy-psychotherapy triangle: Psychiatrist, nonmedical psychotherapist, and patient. Nov, 458-459

Race
Race, violence, and psychopathology. July, 294-297

Rapid Mood Cycling
A case of rapid mood cycling with estrogen: Implications for therapy. Jan, 34-35
State dependence of noradrenergic activity in a rapidly cycling bipolar patient. July, 306-309

Rating Scales
A simple, reliable clinical behavioral scale for assessing demented patients. Jan, 23-24
Correlation of the Hamilton and Carroll depression rating scales: A replication study among psychiatric outpatients. Apr, 167-168
Effects of endogenicity and severity on consistency of standard depression rating scales. June, 260-261

Receptor Studies
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Aug, 331-336

Rhabdomyolysis
Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Aug, 356-357

Salt
The treatment of phenelzine-induced hypotension with salt tablets: Case report. Feb, 89-90

Schizoaffective Disorders
Reply to Clower CG: Schizo-affective disorder: Diagnostic criteria (letter with reply). Mar, 144-145

Schizophrenia
Beyond the therapeutic window: A case presentation. May, 223-225
Cerebral asymmetry in subtypes of schizophrenia. Oct, 423-425
Diagnostic validation of conjoint schizophrenia and alcoholism. July, 300-303
Hypokalemia-induced psychosis in a chronic schizophrenic patient. June, 277-279
Is cholecystokinin an antipsychotic agent? (letter). July, 317
Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study. Apr, 158-163
Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. May, Sec 2, 13-21
Plasma catecholamine metabolites and early response to haloperidol. June, 248-251
Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Mar, 117-119
The dexamethasone suppression test in schizophrenia. Sept, 399-402
The use of depot neuroleptics: Clinical experience in the United States. May, Sec 2, 5-12

Screening Tests
Neurosyphilis in community mental health clinics: A case series. Mar, 127-129
The value of laboratory investigations in elderly psychiatric patients. Mar, 112-116

Sedative Hypnotics
Problems in the use of long-acting hypnotics in older patients. Apr, 176-177

Seizures
Amoxapine-induced seizures: Case report. Aug, 358-359
Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314

Sex Differences
Sex differences in inpatients with major depression. June, 257-259

Shy-Drager Syndrome
Shy-Drager syndrome presenting as depression: Case report. Mar, 137-139

SIADH
Assessment of SIADH in psychosis with a water-loading test: Case report. Jan, 40-41
Drug-induced hyponatremia? (letter). July, 317

Side Effects; see also specific drugs
Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Aug, 331-336
"Trick" movements in facial dystonia. Dec, 519-521

Sleep Disorders, Treatment of
Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. May, 192-195
Depressive psychopathology in male sleep apneics. July, 287-290
Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. Mar, 104-107
Problems in the use of long-acting hypnotics in older patients. Apr, 176-177

Somatization
Depression: Relationship to somatization and chronic medical illness. Mar, Sec 2, 4-12
Somatoform Disorder
Atypical somatoform disorder following infection in children—A depressive equivalent? Mar, 108-111
Stimulants
Treatment of attention deficit and personality disorders with psychostimulants: Case report. Oct, 441-442
Suicidal Behavior
Attempted suicide by ingestion of dentures (letter). Apr, 189
Suicidal behavior: A neglected issue in DSM-III (letter). June, 280
Suicide
A controlled study of suicide pacts. Apr, 154-157
Double suicides: Four modal cases. Nov, 470-472
Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22
Tardive Dyskinesia
Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Jan, 28-30
ECT and tardive dyskinesia (letter). Apr, 188
Propranolol therapy in a patient with panic disorder, tardive dyskinesia, and essential tremor (letter). Nov, 484-485
Thioridazine
Hypothermic coma associated with thioridazine in a myxedematous patient (letter). Apr, 188-189
Thrombotic Thrombocytopenic Purpura
The cost of surviving thrombotic thrombocytopenic purpura: Case report. Nov, 477-479
Thyroid Hormone
Thyroid hormone and the TRH stimulation test in refractory depression. Aug, 345-346
Thyroiditis
Symptomatic thyroiditis and schizophrenia in a six-year-old girl. Jan, 36-37
Tourette's Syndrome
Nifedipine treatment of Tourette's syndrome (letter). Aug, 360
Toxicity
Arthritis associated with lithium toxicity: Case report. Mar, 135-136
Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314
Trazodone
Combined use of trazodone and phenelzine in depression: Case report. Apr, 182-183
Priapism associated with trazodone: Case report. May, 232-233
Trazodone and hemodialysis (letter). Aug, 361
TRH Test
Thyroid hormone and the TRH stimulation test in refractory depression. Aug, 345-346
Triazolam
Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. May, 192-195
Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. Mar, 104-107
Triazolam and tricyclics (letter with reply). Oct, 443
Trichotillomania
MAO inhibitor therapy in trichotillomania associated with depression: Case report. June, 267-268
Tricyclic Antidepressants
Differential response patterns to MAO inhibitors and tricyclics. July, Sec 2, 70-77
Neuroendocrine dysfunction and response to tricyclic antidepressants. Sept, 385-386
The combined use of MAOIs and tricyclics. July, Sec 2, 67-69
Triazolam and tricyclics (letter with reply). Oct, 443
Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. Aug, 353-355
Tyramine
Tyramine studies and the safety of MAOI drugs. July, Sec 2, 59-61
Violence
An evaluation of primary alcoholics with histories of violence. Jan, 3
Race, violence and psychopathology. July, 294-297
Water-Loading Test
Assessment of SIADH in psychosis with a water-loading test: Case report. Jan, 40-41
Yohimbine
Yohimbine and the model anxiety state. Dec, 512-515

AUTHOR INDEX

Aagesen CA see Fawcett J
Aarons SF see Mann JJ
Abrahams LM see Bremner JD
Ackerman D see Jefferson JW
Addad M see Benezech M
Ahles S, Gwirtsman H, Halaris A, Shah P, Schwarcz G, Hill MA: Comparative cardiac effects of maprotiline and doxepin in elderly depressed patients. Nov, 460-465
Aldrich TE see Fishbain DA
Allen RE, Pitts FN Jr: Dexamethasone suppression in depressed elderly outpatients. Sept, 397-398
Allison S see Shader RI
Alterman AI, Ayre FR, Williford WO: Diagnostic validation of conjoint schizophrenia and alcoholism. July, 300-303
Altman EG see Nasr SJ
Amara I see Gillings D
Anderson WH see Kuehnle JC
Andrus PF: Lithium and carbamazepine (letter). Dec, 525
Annable L see Chouinard G
Arndt IC see Greenstein RA
Aronoff M see Clarkin JF
Aronson MD see Hafez H
Atkinson RL: Endocrine and metabolic effects of opiate antagonists. Sept, Sec 2, 20-24
Aulakh CS see Murphy DL
Auth TL see Kwentus JA
Aviles M see Gomez EA
Ayd FJ Jr: Long-term treatment of chronic depression: 15-year experience with doxepin HCl. Mar, Sec 2, 39-46
Ayd FJ Jr see Burch EA Jr
Ayre FR see Alterman AI
Baciewicz G, Yerevanian BI: Thrombocytopenia associated with carbamazepine: Case report and review. July, 315-316
Baker L see Cantwell DP
Ballenger JC see Vieweg WVR
Ban T: Chronic disease and depression in the geriatric population. Mar, Sec 2, 18-24
Barsky S see Fishbain DA
Baxter L, Edell W, Gerner R, Fairbanks L, Gwirtsman H: Dexamethasone suppression test and axis I diagnoses of inpatients with DSM-III borderline personality disorder. Apr, 150-153
Baxter LR Jr: Reversibility of MAO inhibition (letter). May, 234
Baxter LR, Fairbanks L, Gerner RH: Clinical utilization of the dexamethasone suppression test in an inpatient setting. Sept, 393-396
Beeber AR, Kline MD, Pies RW, Manring JM Jr: Hysteroid dysphoria in depressed inpatients. Apr, 164-166
Behar D see VanValkenberg C
Beitman BD, Chiles J, Carlin A: The pharmacotherapy-psychotherapy triangle: Psychiatrist, nonmedical psychotherapist, and patient. Nov, 458-459
Benedetti C see Ward N
Benezech M, Yesavage JA, Addad M, Bourgeois M, Mills M: Homicide by psychotics in France: A five-year study. Feb, 85-86
Berkowitz R see Leff J
Bernstein JG: Pharmacotherapy of geriatric depression. Oct, Sec 2, 30-36
Bernstein JP, Chung SY: Dynamics of the cortisol suppression index in depression. Oct, 433-436
Bertrand WE see Winstead DK
Bialos D see Giller E Jr
Bidder TG see Levy AB
Binder RL, Jonelis FJ: Seborrheic dermatitis: A newly reported side effect of neuroleptics. Mar, 125-126
Birmacher B see Grunhaus L
Bitton V, Melamed E: Coexistence of severe parkinsonism and tardive dyskinesia as side effects of neuroleptic therapy. Jan, 28-30
Black DW, Cadoret RJ: Anorexia nervosa in a 45-year-old man. Sept, 405-406
Black DW, Waziri R: Arthritis associated with lithium toxicity: Case report. Mar, 135-136
Blanchard R see Wilson A
Blum A: Smoking and hyponatremia in psychiatric patients (letter). Aug, 360-361
Bokan JA see Ward N
Boren D see Schmitt R
Bourgeois M see Benezech M
Boutacoff LI see Mitchell JE
Bowers MB Jr, Swigar ME, Jatlow PI, Goicoechea N: Plasma catecholamine metabolites and early response to haloperidol. June, 248-251
Bradwein J see Chouinard G
Brahen LS, Henderson RK, Capone T, Kordal N: Naltrexone treatment in a jail work-release program. Sept, Sec 2, 49-52
Brauzer B see Goldstein BJ
Bremner JD: Fluoxetine in depressed patients: A comparison with imipramine. Oct, 414-419
Bremner JD, Abrahams LM, Crupie JE, McCawley A, Proctor RC, Sathananthan GL: Multicenter double-blind comparison of nomifensine and imipramine for efficacy and safety in depressed outpatients. Apr, Sec 2, 56-59
Brim J, Wetzel R, Reich T, Wood D, Viesselman J, Rutt C: Primary and secondary affective disorder: Part III. Longitudinal differences in depression symptoms. Feb, 64-69
Brocker N see Scharf MB
Brotman AW: Reply to Stewart JW: Antidepressant treatment of bulimia (letter). Oct, 443
Brotman AW, Herzog DB, Woods SW: Antidepressant treatment of bulimia: The relationship between bingeing and depressive symptomatology. Jan, 7-9
Brotman AW see Jenike MA
Brown RD see Mann JJ
Brown RT, Wynne ME, Slimmer LW: Attention deficit disorder and the effect of methylphenidate on attention, behavioral, and cardiovascular functioning. Nov, 473-476
Bryant SG, Guernsey BG, Hokanson JA, Doutre WH: Predicting lithium dose (letter). Feb, 95
Burch EA Jr, Ayd FJ Jr: Reply to Schiff AA: EPS associated with pipothiazines (letter). Mar, 145
Burg B see Nasr SJ
Burstein A: Dream disturbances and flashbacks (letter). Jan, 46
Burton BT see Resnick M
Butler S see Ward N
Butterfield L see Schulz SC
Byerley B see Janowsky DS
Cadoret RJ see Black DW
Caldwell T see Sadler JZ
Cantwell DP, Baker L: Parental mental illness and psychiatric disorders in "at risk" children. Dec, 503-507
Capo T see Schmitt R
Capone T see Brahen LS
Carek DJ, Santos AB Jr: Atypical somatoform disorder following infection in children—A depressive equivalent? Mar, 108-111
Carey RW see Greenberg DB
Carlin A see Beitman BD
Carr DB, Sheehan DV: Panic anxiety: A new biological model. Aug, 323-330
Carroll BJ: Problems with diagnostic criteria for depression. July, Sec 2, 14-18
Carter RG see Manberg PJ
Cassem N see Kaufmann MW
Cavanaugh JJ, Finlayson RE: Rhabdomyolysis due to acute dystonic reaction to antipsychotic drugs. Aug, 356-357
Cavanaugh S von Ammon: Diagnosing depression in the hospitalized patient with chronic medical illness. Mar, Sec 2, 13-17
Cavanaugh S von Ammon: Use of desipramine in the medically ill. Oct, Sec 2, 23-29
Cedars PI see Gitlin MJ
Channabasavanna SM see Gangadhar BN
Charalampous KD see Goldstein BJ
Childress AR see O'Brien CP
Chiles J see Beitman BD
Chouinard G, Bradwein J, Annable L, Jones BD, Ross-Chouinard A: Withdrawal symptoms after long-term treatment with low-potency neuroleptics. Dec, 500-502
Christian MS: Reproductive toxicity and teratology evaluations of naltrexone. Sept, Sec 2, 7-10
Chung SY see Bernstein JP
Claghorn JL, Schroeder J, Goldstein BJ II: Comparison of the electrocardiographic effect of dothiepin and amitriptyline. July, 291-293
Claghorn JL see Feighner JP
Clark DC see Fawcett J
Clarkin JF, Friedman RC, Hurt SW, Corn R, Aronoff M: Affective and character pathology of suicidal adolescent and young adult inpatients. Jan, 19-22
Clower CG: Schizo-affective disorder: Diagnostic criteria. Mar, 144-145
Coble PA see Reynolds CF III
Coccaro EF, Prudic J, Rothpearl A, Nurnberg HG: Clinical utilization of the dexamethasone suppression test. Sept, 382-384
Cohen AJ see Tennant FS Jr
Cohen BM see Gelenberg AJ
Cohen RM see Murphy DL
Cohen S: Drugs in the workplace. Dec, Sec 2, 4-8
Cohn JB: Double-blind crossover comparison of triazolam and lorazepam in the posthypnotic state. Mar, 104-107
Cohn JB: Reply to Jones SD: Triazolam and tricyclics (letter). Oct, 443
Cohn JB, Varga L, Lyford A: A two-center double-blind study of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 68-72
Coleman JH see Johnston JA
Cork RC see Hameroff SR
Corn R see Clarkin JF
Coryell W, House D: The validity of broadly defined hysteria and DSM-III conversion disorder: Outcome, family history, and mortality. June, 252-256
Crago R see Hameroff SR
Cramer M see Zetin M
Crook T: Nomifensine in the depressed elderly patient: Discussion. Apr, Sec 2, 102-103
Crowe RR see Tsuang MT
Crump G see Pellegrini A
Crupie JE see Bremner JD
Curren FC see Gelenberg AJ
Custer RL: Profile of the pathological gambler. Dec, Sec 2, 35-38
D'Achille L see Fishbain DA
Davidson J, Dudley RG Jr, Zung WWK: Introduction. July, Sec 2, 4
Davidson J, Turnbull C: The importance of dose in isocarboxazid therapy. July, Sec 2, 49-52
Davidson J, Zung WWK, Walker JI: Practical aspects of MAO inhibitor therapy. July, Sec 2, 81-84
Davidson J see Krishnan RR; Walker JI; Zung WWK
Davidson W see Wilson A
Davis CM see Ereshefsky L
Davis J see Levy AB; Ostrow D
Davis KL: Discussion. Apr, Sec 2, 104-105
Davis KL see Fiori M
Davis TP see Hameroff SR
DeMet E see Ostrow D
Dencker SJ: The risk/benefit ratio of depot neuroleptics: A Scandinavian perspective. May, Sec 2, 22-27
Denton WH see Zung WWK
Depry D see Neborsky RJ
Desai NG see Gangadhar BN
Devanand DP, Pandurangi AK, Dewan MJ: False-positive dexamethasone suppression test results related to antipsychotic drug withdrawal: Case report. June, 275-276
Dewan MJ see Devanand DP
Divoll M see Greenblatt DJ
Donelan M see Gillings D
Doutre WH see Bryant SG
Doweiko J, Fogel BS, Goldberg RJ: Trazodone and hemodialysis (letter). Aug, 361
Drake ME Jr see Kramer DS

Druff JH see Johnston JA
Dudley RG Jr see Davidson J
Dysken M see Ostrow D
Eberlein-Fries R see Leff J
Eddlemon JK see Johnston JA
Edell W see Baxter L
Ehrman RN see O'Brien CP
Ereshefsky L, Saklad SR, Jann MW, Davis CM, Richards A, Seidel DR: Future of depot neuroleptic therapy: Pharmacokinetic and pharmacodynamic approaches. May, Sec 2, 50-59
Escobar JI see Tuason VB
Evans B see Greenstein RA
Fairbanks L see Baxter L; Baxter LR; Gitlin MJ
Falk WE see Gelenberg AJ
Fann WE, Lyle FA, Higginbotham W: Nomifensine vs. imipramine in depressed inpatients. Apr, Sec 2, 60-62
Fawcett J, Clark DC, Gibbons RD, Aagesen CA, Piani VD, Tilkin JM, Sellers D, Stutzman D: Evaluation of lithium therapy for alcoholism. Dec, 494-499
Fawcett J: Introduction/overview. Mar, Sec 2, 3
Feighner JP, Merideth CH, Claghorn JL: Multicenter placebo-controlled evaluation of nomifensine treatment in depressed outpatients. Apr, Sec 2, 47-51
Feighner JP see Merideth CH
Feinberg T, Goodman B: Affective illness, dementia, and pseudodementia. Mar, 99-103
Fielding S, Szewczak MR: Pharmacology of nomifensine: A review of animal studies. Apr, Sec 2, 12-20
Finlayson RE see Cavanaugh JJ
Fiori M, Davis KL: Possible clinical applications of laboratory tests in depression. Apr, Sec 2, 6-11
Fishbain DA, D'Achille L, Barsky S, Aldrich TE: A controlled study of suicide pacts. Apr, 154-157
Fogel BS see Doweiko J
Fowler RC see Young D
Foy JL see Kwentus JA
Fram DH see Targum SD
Frances AJ see Mann JJ
Frazier H see Schmitt R
Freinhar JP: Alprazolam and premenstrual syndrome (letter). Dec, 526
Friedel RO: Relationship of desipramine plasma levels to therapeutic response: A critical reappraisal of the data. Oct, Sec 2, 46-49
Friedel RO see Schulz SC
Friedman RC see Clarkin JF
Gangadhar BN, Desai NG, Channabasavanna SM: Amantadine in the neuroleptic malignant syndrome (letter). Dec, 526
Garber D see Zetin M
Garicano M see Schulz SC
Garrick NA see Murphy DL
Garver DL see Mavroidis ML
Garvey M see Hwang S; Tuason VB
Gawin FH see Kleber HD
Gelenberg AJ, Wojcik JD, Lydiard RB, McCormick MGF, Falk WE, Hicks RH, Curren FC, Cohen BM: Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients. Feb, 54-59
George DT see Zung WWK
Georgia EH: Double-blind comparison of the efficacy and safety of nomifensine maleate vs. placebo in depressed outpatients. Apr, Sec 2, 43-46
Gerner R see Baxter L
Gerner RH see Baxter LR; Gitlin MJ
Gershon S see Goodnick P; Kelwala S; Pomara N
Giannini AJ, Price WA: Amoxapine-induced seizures: Case report. Aug, 358-359
Giannini AJ see Price WA
Gibbons RD see Fawcett J
Giller E Jr, Bialos D, Harkness L, Riddle M: Assessing treatment response to the monoamine oxidase inhibitor isocarboxazid. July, Sec 2, 44-48
Gillespie HK see Henauer SA
Gillings D, Grizzle J, Koch G, Rickels K, Amara I, Donelan M, Hardiman S, Nash R, Sollecito W, Stager W: Pooling 12 nomifensine studies for efficacy generalizability. Apr, Sec 2, 78-84
Ginzburg HM, Glass WJ: The role of the National Institute on Drug Abuse in the development of naltrexone. Sept, Sec 2, 4-6
Gitlin MJ, Gwirtsman H, Fairbanks L, Sternbach HA, Cedars PI, Gerner RH: Dexamethasone suppression test and treatment response. Sept, 387-389
Glass WJ see Ginzburg HM
Glassman AH see Stewart JW
Glazer WM: Depot fluphenazine: Risk/benefit ratio. May, Sec 2, 28-35
Gloger S see Grunhaus L
Goff P see Scharf MB
Goicoechea N see Bowers MB
Gold MS see Washton AM
Gold PW see Roy-Byrne P
Goldberg RJ see Doweiko J
Goldstein BJ, Brauzer B, Kentsmith D, Rosenthal S, Charalampous KD: Double-blind placebo-controlled multicenter evaluation of the efficacy and safety of nomifensine in depressed outpatients. Apr, Sec 2, 52-55
Goldstein BJ II see Claghorn JL
Goldstein JA: Alpha-2 agonists as analgesics (letter). Jan, 46
Goldstein JA: Nifedipine treatment of Tourette's syndrome (letter). Aug, 360
Gomez EA, Aviles M: Neurosyphilis in community mental health clinics: A case series. Mar, 127-129
Goode DJ: Reply to Clower CG: Schizo-affective disorder: Diagnostic criteria (letter). Mar, 145
Goodman B see Feinberg T
Goodnick P, Gershon S: Chemotherapy of cognitive disorders in geriatric subjects. May, 196-209
Goodwin DW: Speculations on the cause(s) of alcoholism. Dec, 491-493
Goodwin DW: Studies of familial alcoholism: A review. Dec, Sec 2, 14-17
Greenberg DB, Carey RW: The cost of surviving thrombotic thrombocytopenic purpura: Case report. Nov, 477-479
Greenberg RD see Targum SD
Greenblatt DJ, Shader RI, Divoll M, Harmatz JS: Adverse reactions to triazolam, flurazepam, and placebo in controlled clinical trials. May, 192-195
Greenblatt DJ see Shader RI
Greenstein RA, Arndt IC, McLellan AT, O'Brien CP, Evans B: Naltrexone: A clinical perspective. Sept, Sec 2, 25-28
Grizzle J see Gillings D
Grunhaus L, Gloger S, Birmacher B: Clomipramine treatment for panic attacks in patients with mitral valve prolapse. Jan, 25-27
Guernsey BG see Bryant SG
Gultekin A see Lippman SB
Gwirtsman HE, Roy-Byrne P, Lerner L, Yager J: Bulimia in men: Report of three cases with neuroendocrine findings. Feb, 78-81
Gwirtsman H see Ahles S; Baxter L; Gitlin MJ
Hafez H, Strauss JS, Aronson MD, Holt C: Hypokalemia-induced psychosis in a chronic schizophrenic patient. June, 277-279
Halaris A see Ahles S; Ostrow D
Halikas JA, Lyttle MD, Morse CL: Skid row alcoholism—An objective definition for use in detoxification and treatment planning. May, 214-216
Halikas JA see Weller RA
Hameroff SR, Weiss JL, Lerman JC, Cork RC, Watts KS, Crago R, Neuman CP, Womble JR, Davis TP: Doxepin's effects on chronic pain and depression. Mar, Sec 2, 47-53
Hardiman S see Gillings D; Yakabow AL
Harkness L see Giller E Jr
Harmatz JS see Greenblatt DJ; Shader RI
Harmon RL see Targum SD
Harrison W see Liebowitz MR; Quitkin FM
Harrow M see Ostrow D
Harsch HH see Lanska D
Hatsikami D see Mitchell JE
Haycox JA: A simple, reliable clinical behavioral scale for assessing demented patients. Jan, 23-24
Henauer SA, Gillespie HK, Hollister LE: Yohimbine and the model anxiety state. Dec, 512-515
Henderson RK see Brahen LS
Hendler N: Depression caused by chronic pain. Mar, Sec 2, 30-37
Hendrickson G see Merideth CH
Henningfield JE: Pharmacologic basis and treatment of cigarette smoking. Dec, Sec 2, 24-34
Heptner W, Hornke I, Uihlein M: Kinetics and metabolism of nomifensine. Apr, Sec 2, 21-25
Hermann BP, Melyn M: Effects of carbamazepine on interictal psychopathology in TLE with ictal fear. Apr, 169-171
Herzog C see Tollefson G
Herzog DB see Brotman AW
Hicks RH see Gelenberg AJ
Higginbotham W see Fann WE
Hill MA see Ahles S
Hindmarch D see Hsu LKG
Hirschowitz J see Mavroidis ML
Ho I see Lassman HB
Hogarty GE: Depot neuroleptics: The relevance of psychosocial factors—A United States perspective. May, Sec 2, 36-42
Hokanson JA see Bryant SG
Holder D see Hsu LKG
Holland JC see Massie MJ
Hollister LE: Preface. Apr, Sec 2, 4
Hollister LE: Discussion. Apr, Sec 2, 100-101
Hollister LE see Henauer SA
Holt C see Hafez H
Hooberman D, Stern TA: Treatment of attention deficit and borderline personality disorders with psychostimulants: Case report. Oct, 441-442
Hornke I see Heptner W
Horwitz IM see Kornhaber A
House D see Coryell W
Hsu LKG, Holder D, Hindmarch D, Phelps C: Bipolar illness preceded by anorexia nervosa in identical twins. June, 262-266
Hullett FJ, Levy AB, Tachiki KH: Serum imipramine concentrations lower than plasma levels. Dec, 516-518
Hurt SW see Clarkin JF
Hwang S, Zander J, Garvey M: Dexamethasone suppression test: Use of two different dexamethasone doses. Sept, 390-392
Iwamoto ET see Martin CA
Jacoby CG see Tsai LY
Jann MW see Ereshefsky L
Janowsky DS, Byerley B: Desipramine: An overview. Oct, Sec 2, 3-9
Janowsky DS see Neborsky RJ
Jansen W, Siegfried K: Nomifensine in geriatric inpatients: A placebo-controlled study. Apr, Sec 2, 63-67
Jatlow PI see Bowers MB Jr
Jayatilaka A see Luna OC
Jefferson JW, Kaufman P, Ackerman D: Tear lithium concentration: A measurement of dubious clinical value. July, 304-305
Jeffries JJ see Remington G; Sawyer J
Jenike MA, Brotman AW: The EEG in obsessive-compulsive disorder. Mar, 122-124
Jenkins PL: Is cholecystokinin an antipsychotic agent? (letter). July, 317
Jessee SS: Reply to Weston AP: Treatments for neuroleptic malignant syndrome (letter). Mar, 144
Jewell SW see Rich CL
Jobe TH see Nasr SJ
Johnson DAW: Observations on the use of long-acting depot neuroleptic injections in the maintenance therapy of schizophrenia. May, Sec 2, 13-21
Johnson RW: Drug-induced hyponatremia? (letter). July, 317
Johnston JA, Powers DA, Coleman JH, Eddlemon JK, May CN, Druff JH: Protocols for the use of psychoactive drugs: Part III. Protocol for the treatment of bipolar affective disorder with lithium. May, 210-213
Jonelis FJ see Binder RL
Jones BD see Chouinard G
Jones SD: Triazolam and tricyclics (letter). Oct, 443
Joseph AB see Kuehnle JC
Kalayam B see Meyers BS
Kane JM: The use of depot neuroleptics: Clinical experience in the United States. May, Sec 2, 5-12
Kanter DR see Mavroidis ML
Katon W: Depression: Relationship to somatization and chronic medical illness. Mar, Sec 2, 4-12
Katz I see Lindenmeyer JP
Kaufman P see Jefferson JW

Kaufmann MW, Cassem N, Murray G, MacDonald D: The use of methylphenidate in depressed patients after cardiac surgery. Feb, 82-84
Kelwala S, Pomara N, Stanley M, Sitaram N, Gershon S: Lithium-induced accentuation of extrapyramidal symptoms in individuals with Alzheimer's disease. Aug, 342-344
Kentsmith D see Goldstein BJ
Kessler K see Targum SD
Khosla N see Scharf MB
Kiefer MW see Olivera AA
Kirstein L: Neuroendocrine dysfunction and response to tricyclic antidepressants. Sept, 385-386
Kleber HD, Kosten TR: Naltrexone induction: Psychologic and pharmacologic strategies. Sept, Sec 2, 29-38
Kleber HD, Gawin FH: The spectrum of cocaine abuse and its treatment. Dec, Sec 2, 18-23
Klein DF see Liebowitz MR
Kline MD see Beeber AR
Koch G see Gillings D
Koenigsberg HW: Manic pseudodementia: Case report. Mar, 132-134
Kolman PBR: The value of laboratory investigations of elderly psychiatric patients. Mar, 112-116
Kordal N see Brahen LS
Korahaber A, Horwitz IM: A comparison of clomipramine and doxepin in neurotic depression. Aug, 337-341
Kosten TR see Kleber HD
Kramer DS, Drake ME Jr: Assessment of SIADH in psychosis with a water-loading test: Case report. Jan, 40-41
Kramer M, Schoen LS: Problems in the use of long-acting hypnotics in older patients. Apr, 176-177
Krishnan KRR, Swartz MS, Larson MJ, Santoliquido G: Funeral mania in recurrent bipolar affective disorders: Reports of three cases. July, 310-311
Krishnan RR, Davidson J, Miller R: MAO inhibitor therapy in trichotillomania associated with depression: Case report. June, 267-268
Kuehnle JC, Joseph AB, Anderson WH: Carbamazepine in chronic patients with EEG abnormalities (letter). Sept, 407
Kuipers L see Leff J
Kupfer DJ see Reynolds CF III
Kwee IL see Nakada T
Kwentus JA, Auth TL, Foy JL: Shy-Drager syndrome presenting as depression: Case report. Mar, 137-139
Lahmeyer H see Parker J
Lanska D, Harsch HH: Hypothermic coma associated with thioridazine in a myxedematous patient (letter). Apr, 188-189
Lansky MR, Selzer J: Priapism associated with trazodone therapy: Case report. May, 232-233
Larson MJ see Krishnan KRR
Lassman HB, Puri SK, Ho I, Sabo R, Rosenkilde HC: The pharmacokinetics and bioavailability of nomifensine maleate in healthy men. Apr, Sec 2, 26-32
Laux G, Schlesser MA, Rush AJ, Orsulak P, Weissenburger J: A comparison of the cortisol suppression index and the dexamethasone suppression test. Oct, 431-432
Lawson WB, Yesavage JA, Werner PD: Race, violence, and psychopathology. July, 294-297
Leavell SR see Prakash R
Lee H see Nakada T
Leff J, Kuipers L, Berkowitz R, Eberlein-Fries R, Sturgeon D: Psychosocial relevance and benefit of neuroleptic maintenance: Experience in the United Kingdom. May, Sec 2, 43-49
Lerer B: ECT and tardive dyskinesia (letter). Apr, 188
Lerman JC see Hameroff SR
Lerner AM see Nakada T
Lerner L see Gwirtsman HE
Lesar T see Tollefson G
Lesser I: Carbamazepine and desipramine: A toxic reaction (letter). Aug, 360
Levy AB, Davis J, Bidder TG: Successful treatment of endogenous depression with alprazolam in a patient with recent cardiac disease: Case report. Nov, 480-481
Levy AB see Hullett FJ
Levy AB: Delirium and seizures due to abrupt alprazolam withdrawal: Case report. Jan, 38-39
Licamele WL see Rosse RB
Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison W, Rabkin JG, Tricamo E, Markowitz JS, Klein DF: Psychopharmacologic validation of atypical depression. July, Sec 2, 22-25
Liebowitz M see Quitkin FM
Lindenmeyer JP, Smith D, Katz I: Radioreceptor assay of neuroleptics in refractory chronic schizophrenic patients. Mar, 117-119
Ling W, Wesson DR: Naltrexone treatment for addicted health-care professionals: A collaborative private practice experience. Sept, Sec 2, 46-48
Lippman SB, Manshadi MS, Gultekin A: Lithium in a patient with renal failure on hemodialysis (letter). Oct, 444
Lippmann SB see Pellegrini A
Litovitz GL: Amitriptyline and contact lenses (letter). Apr, 188
Lo M-W see Myer MC
Locniskar A see Shader RI
Lowenstein RJ see Putnam FW
Lowry M see VanValkenberg C
Luna OC, Jayatilaka A, Walker V: Amoxapine and extrapyramidal symptoms (letter). Sept, 407
Lydiard RB see Gelenberg AJ
Lyford A see Cohn JB
Lyle FA see Fann WE
Lyttle MD see Halikas JA
MacDonald D see Kaufmann MW
Mahorney S see Zung WWK
Maini K see Wilson A
Mallott D see Winstead DK
Manberg PJ, Carter RG: Bupropion in the treatment of psychotic depression: Two case reports. May, 230-231
Mann A see Tennant FS Jr
Mann JJ, Aarons SF, Frances AJ, Brown RD: Studies of selective and reversible monoamine oxidase inhibitors. July, Sec 2, 62-66
Manring JM Jr see Beeber AR
Manshadi M see Pellegrini A
Manshadi MS see Lippman SB
Markowitz J see Quitkin FM
Markowitz JS see Liebowitz MR
Martin CA, Iwamoto ET: Diethylpropion-induced psychosis reprecipitated by an MAO inhibitor: Case report. Mar, 130-131
Massie MJ, Holland JC: Diagnosis and treatment of depression in the cancer patient. Mar, Sec 2, 25-29
Mavroidis ML, Kanter DR, Hirschowitz J, Garver DL: Fluphenazine plasma levels and clinical response. Sept, 370-373
May CN see Johnston JA
McCawley A see Bremner JD
McCormick MGF see Gelenberg AJ
McEachran AB see Reynolds CF III
McGrath P see Quitkin FM
McGrath PJ see Liebowitz MR
McLellan AT see Greenstein RA; O'Brien CP
McLellan T see O'Brien CP
McRae L see Wilson A
Mei-Tal V see Meyers BS
Melamed E see Bitton V
Melyn M see Hermann BP
Merideth CH, Feighner JP, Hendrickson G: A double-blind comparative evaluation of the efficacy and safety of nomifensine, imipramine, and placebo in depressed geriatric outpatients. Apr, Sec 2, 73-77
Merideth CH see Feighner JP
Meyer MC, Straughn AB, Lo MW, Schary WL, Whitney CC: Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration. Sept, Sec 2, 15-19
Meyers BS, Kalayam B, Mei-Tal V: Late-onset delusional depression: A distinct clinical entity? Aug, 347-349
Miller R see Krishnan RR
Mills M see Benezech M
Mitchell JE, Pyle RL, Hatsikami D, Boutacoff LI: The dexamethasone suppression test in patients with bulimia. Dec, 508-511
Moldawsky RJ: Hepatotoxicity associated with maprotiline therapy: Case report. Apr, 178-179
Morse C see Weller RA
Morse CL see Halikas JA
Mukherjee S see Rosen AM
Munjack DJ: The treatment of phenelzine-induced hypotension with salt tablets: Case report. Feb, 89-90
Munson E see Neborsky RJ
Murphy DL, Garrick NA, Aulakh CS, Cohen RM: New contributions from basic science to understanding the effects of monoamine oxidase inhibiting antidepressants. July, Sec 2, 37-43
Murray G see Kaufmann NW
Nakada T, Lee H, Kwee IL, Lerner AM: Epileptic Kluver-Bucy syndrome: Case report. Feb, 87-88
Narasimhachari N see Schulz S
Nash R see Gillings D
Nash RJ see Yakabow AL
Nasr SJ, Altman EG, Rodin MB, Jobe TH, Burg B: Correlation of the Hamilton and Carroll depression rating scales: A replication study among psychiatric outpatients. Apr, 167-168
Nasrallah HA see Tsai LY
Neborsky RJ, Janowsky DS, Perel M, Munson E, Depry D: Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. Jan, 10-13
Neil JF see Rich CL
Nelson JC: Use of desipramine in depressed inpatients. Oct, Sec 2, 10-16
Nelson WH, Orr WW Jr, Shane SR, Stevenson JM: Hypothalamic-pituitary-adrenal axis activity and age in major depression. Mar, 120-121
Neuman CP see Hameroff SR
Nies A: Differential response patterns to MAO inhibitors and tricyclics. July, Sec 2, 70-77
Nora LM see Weiner WJ
Nurnberg HG see Coccaro EF
O'Brien CP: Introduction. Sept, Sec 2, 3
O'Brien CP: Summary. Sept, Sec 2, 57-58
O'Brien CP, Childress AR, McLellan AT, Ternes J, Ehrman RN: Use of naltrexone to extinguish opioid-conditioned responses. Sept, Sec 2, 53-56
O'Brien CP, Woody GE, McLellan T: Psychiatric disorders in opioid-dependent patients. Dec, Sec 2, 9-13
O'Brien CP see Greenstein RA
O'Donnell DJ see Reiss AL
Olivera AA, Kiefer MW: Propranolol therapy in a patient with panic disorder, tardive dyskinesia and essential tremor (letter). Nov, 484-485
Oppenheim G: A case of rapid mood cycling with estrogen: Implications for therapy. Jan, 34-35
O'Rourke CJ see Ravi SD
Orr WW Jr see Nelson WH
Orsulak P see Laux G
Ostrow D, Halaris A, Dysken M, DeMet E, Harrow M, Davis J: State dependence of noradrenergic activity in a rapidly cycling bipolar patient. July, 306-309
Overall JE: Efficacy of nomifensine in different depressive syndromes. Apr, Sec 2, 85-88
Overman CA see Shore D
Pandurangi AK see Devanand DP
Parker J, Lahmeyer H: Maprotiline poisoning: A case of cardiotoxicity and myoclonic seizures. July, 312-314
Pary RJ see Shader RI
Pellegrini A, Lippmann SB, Crump G, Manshadi M: Psychiatric aspects of complex partial seizures: Case report. June, 269-271
Perel JM see Neborsky RJ
Phelps C see Hsu LKG
Phillips M see Ward N
Pisani VD see Fawcett J
Pies RW see Beeber AR
Pitts FN Jr: Arthur Watts: Research in clinical practice (editorial). Feb, 50
Pitts FN Jr: Disulfiram implantation (editorial). June, 241
Pitts FN Jr: DST and axis I diagnoses in borderline personality disorder (editorial). Apr, 149
Pitts FN Jr: Editorial. Sept, 380-381
Pitts FN Jr: Editorial. Oct, 430
Pitts FN Jr see Allen RE
Pomara N, Gershon S: Treatment-resistant depression in an elderly patient with pancreatic carcinoma: Case report. Oct, 439-440
Pomara N: Suicidal behavior: A neglected issue in DSM-III (letter). June, 280
Pomara N see Kelwala S
Post RM see Putnam FW; Roy-Byrne P
Pottash AC see Washton AM

Powers DA see Johnston JA
Prakash R, Leavell SR: Status epilepticus with unilateral ECT: Case report. Sept, 403-404
Preskorn SH see Ritchie KS
Price WA, Giannini AJ: Attempted suicide by ingestion of dentures (letter). Apr, 189
Price WA see Giannini AJ
Proctor RC see Bremner JD
Prudic J see Coccaro EF
Puri SK see Lassman HB
Putnam D see Sandler AP
Putnam FW, Lowenstein RJ, Silberman EJ, Post RM: Multiple personality disorder in a hospital setting. Apr, 172-175
Pyle RL see Mitchell JE
Quitkin FM, Harrison W, Liebowitz M, McGrath P, Rabkin JG, Stewart J, Markowitz J: Defining the boundaries of atypical depression. July, Sec 2, 19-21
Quitkin FM see Liebowitz MR
Rabkin JG see Liebowitz MR; Quitkin FM
Rasmussen SA, Tsuang MT: The epidemiology of obsessive compulsive disorder. Nov, 450-457
Ravi SD, Roach FL, O'Rourke CJ: Neurosyphilis and late onset mental changes in the elderly (letter). Nov, 484
Rawson RA see Tennant FS Jr
Razani J see White J
Reich T see Brim J
Reiss AL, O'Donnell DJ: Carbamazepine-induced mania in two children: Case report. June, 272-274
Remington G, Jeffries JJ: The role of cerebral arteriovenous malformations in psychiatric disturbances: Case report. May, 226-229
Resnick M, Burton BT: Droperidol vs. haloperidol in the initial management of acutely agitated patients. July, 298-299
Reynolds CF III, Kupfer DJ, McEachran AB, Taska LS, Sewitch DE, Coble PA: Depressive psychopathology in male sleep apneics. July, 287-290
Rich CL, Spiker DG, Jewell SW, Neil JF: DSM-III, RDC, and ECT: Depressive subtypes and immediate response. Jan, 14-18
Rich CL see Young D
Richards A see Ereshefsky L
Richelson E: Neuroleptic affinities for human brain receptors and their use in predicting adverse effects. Aug, 331-336
Rickels K: Introduction. Apr, Sec 2, 5
Rickels K see Gillings D
Riddle M see Giller E Jr
Ritchie KS, Preskorn SH: Mania induced by metoclopramide: Case report. Apr, 180-181
Roach FL see Ravi SD
Rodin MB see Nasr SJ
Roose SP see Stewart JW
Rosen AM, Mukherjee S, Shinbach K: The efficacy of ECT in phencyclidine-induced psychosis. May, 220-222
Rosenbaum JF: Treatment of outpatients with desipramine. Oct, Sec 2, 17-22
Rosenfeld A see Spiegel D
Rosenkilde HC see Lassman HB
Rosenkrantz H: Physiologic and morphologic changes and incidence of neoplasms in mice and rats fed naltrexone HCl for 24 months. Sept, Sec 2, 11-14
Rosenthal S see Goldstein BJ
Ross-Chouinard A see Chouinard G
Rosse RB, Licamele WL: Slow-release methylphenidate: Problems when children chew tablets (letter). Dec, 525
Rothpearl A see Coccaro EF
Roy-Byrne P, Rubinow DR, Gold PW, Post RM: Possible antidepressant effect of oral contraceptives: Case report. Aug, 350-352
Roy-Byrne P see Gwirtsman HE
Rubinow DR see Roy-Byrne P
Rush AJ see Laux G; Sadler JZ
Russell JW see Schuckit MA
Rutt C see Brim J
Sabo R see Lassman HB
Sadler JZ, Rush AJ, Caldwell T: Secondary agoraphobia: Two case reports. Nov, 482-483
Saklad SR see Ereshefsky L
Salerian AJ see Targum SD
Sandler AP, Thompson J, Putney D: Symptomatic thyroiditis and schizophrenia in a six-year-old girl. Jan, 36-37
Santoliquido G see Krishnan KRR
Santos AB see Carek DJ
Sathananthan GL see Bremner JD
Sawyer J, Jeffries JJ: The dexamethasone suppression test in schizophrenia. Sept, 399-402
Scharf MB, Khosla N, Brocker N, Goff P: Differential amnestic properties of short- and long-acting benzodiazepines. Feb, 51-53
Schary WL see Meyer MC
Schiele B see Tuason VB
Schiff AA: EPS associated with pipothiazines (letter). Mar, 145
Schlesser MA see Laux G
Schmitt R, Capo T, Frazier H, Boren D: Cranial electrotherapy stimulation treatment of cognitive brain dysfunction and chemical dependence. Feb, 60-63
Schoen LS see Kramer M
Schroeder J see Claghorn JL
Schuckit MA: Differences in plasma cortisol after ingestion of ethanol in relatives of alcoholics and controls: Preliminary results. Sept, 374-376
Schuckit MA, Russell JW: An evaluation of primary alcoholics with histories of violence. Jan, 3-6
Schulz SC, Butterfield I, Garicano M, Narasimhachari N, Friedel RO: Beyond the therapeutic window: A case presentation. May, 223-225
Schwartz BD see Winstead DK
Schwarcz G see Ahles S
Seidel DR see Ereshefsky L
Sellers D see Fawcett J
Selzer J see Lansky MR
Sewitch DE see Reynolds CF III
Shader RI, Pary RJ, Harmatz JS, Allison S, Locniskar A, Greenblatt DJ: Plasma concentrations and clinical effects after single oral doses of prazepam, clorazepate, and diazepam. Oct, 411-413
Shader RI see Greenblatt DJ
Shah P see Ahles S
Shane SR see Nelson WH
Sheehan DV: Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: Implications for classification. July, Sec 2, 29-36
Sheehan DV see Carr DB
Shinbach K see Rosen AM
Shore D, Overman CA, Wyatt RJ: More on diagnosing Alzheimer's disease (letter). June, 280
Siegfried K, Taeuber K: Pharmacodynamics of nomifensine: A review of studies in healthy subjects. Apr, Sec 2, 33-38
Siegfried K see Jansen W
Silberman EJ see Putnam FW
Simpson G see White K
Simpson GM, White K: Tyramine studies and the safety of MAOI drugs. July, Sec 2, 59-61
Simpson GM: A brief history of depot neuroleptics. May, Sec 2, 3-4
Sitaram N see Kelwala S
Sklansky GJ see Zetin M
Slimmer LW see Brown RT
Smith D see Lindenmeyer JP
Sollecito W see Gillings D
Spengler D see Ward N
Spiegel D, Rosenfeld A: Spontaneous hypnotic age regression. Dec, 522-524
Spiker DG see Rich CL
Stager W see Gillings D
Stahl SM: Regulation of neurotransmitter receptors by desipramine and other antidepressant drugs: The neurotransmitter receptor hypothesis of antidepressant action. Oct, Sec 2, 37-45
Stanley M see Kelwala S
Stern TA see Hooberman D
Sternbach HA see Gitlin MJ
Stevenson JM see NelsonWH
Stewart J see Quitkin FM
Stewart JW: Antidepressant treatment of bulimia (letter). Oct, 443
Stewart JW, Walsh BT, Wright L, Roose SP, Glassman AH: An open trial of MAO inhibitors in bulimia. May 217-219
Stewart JW see Liebowitz MR
Stonier PD: A review of the clinical safety and tolerability of nomifensine. Apr, Sec 2, 89-95
Stratas NE: A double-blind study of the efficacy and safety of dothiepin hydrochloride in the treatment of major depressive disorder. Nov, 466-469
Straughn AB see Meyer MC
Strauss JS see Hafez H
Sturgeon D see Leff J
Stutzman D see Fawcett J
Swartz CM: Predicting lithium requirements (letter). Feb, 95-96
Swartz MS see Krishnan KRR
Swigar ME see Bowers MB Jr
Szewczak MR see Fielding S
Tachiki KH see Hullett FJ
Taeuber K see Siegfried K
Targum SD, Greenberg RD, Harmon RL, Kessler K, Salerian AJ, Fram DH: Thyroid hormone and the TRH stimulation test in refractory depression. Aug, 345-346
Taska LS see Reynolds CF III
Tennant FS Jr, Rawson RA, Cohen AJ, Mann A: Clinical experience with naltrexone in suburban opioid addicts. Sept, Sec 2, 42-45
Ternes J see O'Brien CP
Thompson J see Sandler AP
Tilkin FM see Fawcett J
Tollefson G, Lesar T, Herzog C: Atrial flutter and maprotiline: Case report. Jan, 31-33
Tollefson G: Neuropsychiatric sequelae and cephalothin (letter). Feb, 96
Tollefson G: Reply to Baxter LR: Reversibility of MAO inhibition (letter). May, 234
Tricamo E see Liebowitz MR
Trimble MR: Epilepsy, antidepressants, and the role of nomifensine. Apr, Sec 2, 39-42
Tsai LY, Nasrallah HA, Jacoby CG: Cerebral asymmetry in subtypes of schizophrenia. Oct, 423-425
Tsuang MT, Winokur G, Crowe RR: Psychiatric disorders among relatives of surgical controls. Oct, 420-422
Tsuang MT see Rasmussen SA
Tuason VB, Escobar JI, Garvey M, Schiele B: Loxapine versus chlorpromazine in paranoid schizophrenia: A double-blind study. Apr, 158-163
Turnbull C see Davidson J
Uihlein M see Heptner W
VanValkenberg C, Winokur G, Behar D, Lowry M: Depressed women with panic attacks. Sept, 367-369
Varga L see Cohn JB
Viesselman J see Brim J
Vieweg WVR, Yazel JJ, Ballenger JC: Tricyclic antidepressant use in a patient with bundle branch blocks and ventricular ectopy. Aug, 353-355
Walker JI, Davidson J, Zung WWK: Patient compliance with MAO inhibitor therapy. July, Sec 2, 78-80
Walker JI see Davidson J
Walker V see Luna OC
Walsh AC: Anticoagulant therapy in combined affective-organic disorders (letter). Oct, 444
Walsh BT see Stewart JW
Ward N, Bokan JA, Phillips M, Benedetti C, Butler S, Spengler D: Antidepressants in concomitant chronic back pain and depression: Doxepin and desipramine compared. Mar, Sec 2, 54-57
Washton AM, Pottash AC, Gold MS: Naltrexone in addicted business executives and physicians. Sept, Sec 2, 39-41
Watts CAH: Depressive disorders in the community: The scene in Great Britain, 1965. Feb, 70-77
Watts KS see Hameroff SR
Wazivi R see Black DW
Weiner WJ, Nora LM: "Trick" movements in facial dystonia. Dec, 519-521
Weiss JL see Hameroff SR
Weissenburger J see Laux G
Weller RA, Halikas JA, Morse C: Alcohol and marijuana: Comparison of use and abuse in regular marijuana users. Sept, 377-379
Werner PD see Lawson B
Wesson DR see Ling W
West AP: Treatments for neuroleptic malignant syndrome (letter). Mar, 144
Wetzel R see Brim J
White J, White K, Razani J: Effects of endogenicity

and severity on consistency of standard depression rating scales. June, 260-261

White K, Simpson G: The combined use of MAOIs and tricyclics. July, Sec 2, 67-69

White K see Simpson GM; White J

Whitney CC see Meyer MC

Williford WD see Alterman AI

Wilson A, Blanchard R, Davidson W, McRae L, Maini K: Disulfiram implantation: A dose response trial. June, 242-247

Winokur G see Tsuang MT; VanValkenberg C

Winstead DK, Schwartz BD, Mallott D, Bertrand WE: Biorhythms revisited: Rhythm and blues? Oct, 426-429

Wojcik JD see Gelenberg AJ

Womble JR see Hameroff SR

Wood D see Brim J

Woodruff WW III see Zung WWK

Woods SW see Brotman AW

Wright L see Stewart JW

Woody GE see O'Brien CP

Wyatt RI see Shore D

Wynne ME see Brown RT

Yager J see Gwirtsman HE

Yakabow AL, Hardiman S, Nash RJ: An overview of side effects and long-term experience with nomifensine from United States clinical trials. Apr, Sec 2, 96-99

Yazel JJ see Vieweg WVR

Yerevanian BI see Baciewicz G

Yesavage JA see Benezech M; Lawson WB

Young D, Rich CL, Fowler RC: Double suicides: Four modal cases. Nov, 470-472

Zander J see Hwang S

Zetin M: Combined use of trazodone and phenelzine in depression: Case report. Apr, 182-183

Zetin M, Cramer M, Garber D: Reply to Swartz CM: Predicting lithium requirements (letter). Feb, 96

Zetin M, Garber D, Cramer M: Reply to Bryant SG et al: Predicting lithium dose (letter). Feb, 95

Zetin M, Sklansky GJ, Cramer M: Sex differences in inpatients with major depression. June, 257-259

Zisook S: Side effects of isocarboxazid. July, Sec 2, 53-58

Zung WWK, Mahorney SL, Davidson J: Classification of depressive disorders: A multiaxial approach. July, Sec 2, 5-13

Zung WWK, George DT, Woodruff WW III, Mahorney SL: Symptom perception by nonpsychiatric physicians in evaluating for depression. July, Sec 2, 26-28

Zung WWK, Denton WH, Mahorney S: Cortisol suppression index: A further evaluation. Oct, 437-438

Zung WWK see Davidson J; Walker JI